Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
Evidence Explorer
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
ClinicalTrials.gov (27)
GLP-1R Agonist Treatment for Opioid Use Disorder
Phase PHASE2 · RECRUITING · Sponsor: Milton S. Hershey Medical Center
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Phase PHASE2 · RECRUITING · Sponsor: Antag Therapeutics
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Phase NA · NOT_YET_RECRUITING · Sponsor: Oelisoa Andriankaja
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
GLP-1R Actions on Muscle and the Skeleton
Phase PHASE4 · ACTIVE_NOT_RECRUITING · Sponsor: Pennington Biomedical Research Center
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Phase PHASE1 · RECRUITING · Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Different Medications to Induce Labor
Phase PHASE3 · RECRUITING · Sponsor: Icahn School of Medicine at Mount Sinai
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Phase PHASE1 · RECRUITING · Sponsor: Barbara Ann Karmanos Cancer Institute
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase PHASE1 · RECRUITING · Sponsor: Novo Nordisk A/S
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Phase NA · COMPLETED · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism
Phase NA · RECRUITING · Sponsor: Massachusetts General Hospital
Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)
Phase NA · NOT_YET_RECRUITING · Sponsor: Ochsner Health System
Tolerability of MDMA in Schizophrenia
Phase PHASE1/PHASE2 · RECRUITING · Sponsor: Anya Bershad, MD, PhD
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Phase PHASE1 · RECRUITING · Sponsor: Elizabeth Austen Lawson
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
Phase EARLY_PHASE1 · RECRUITING · Sponsor: Massachusetts General Hospital
Patient Empowerment and Agency Through Intrapartum Counseling and Education
Phase NA · COMPLETED · Sponsor: Oregon Health and Science University
Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk
Phase NA · NOT_YET_RECRUITING · Sponsor: Florida State University
Open, Randomized Feasibility Trial on the Safety and Performance of the INGA Catheter for Labor Induction
Phase NA · RECRUITING · Sponsor: Aalto University
The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy
Phase EARLY_PHASE1 · NOT_YET_RECRUITING · Sponsor: Alex Ekwueme Federal University Teaching Hospital
PubMed (73)
Circulating levels of PYY are increased in individuals with bile acid diarrhoea.
The Journal of clinical endocrinology and metabolism · 2026 Jul 24 · DOI: 10.1210/clinem/dgag295
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100304
Clinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.
American journal of translational research · 2026 · DOI: 10.62347/WNDZ4386
GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.
Frontiers in neurology · 2026 · DOI: 10.3389/fneur.2026.1858507
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111313
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026 Jul 21 · DOI: 10.1186/s43044-026-00767-y
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Jul 18 · DOI: 10.1007/s00210-026-05646-6
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Appetite · 2026 Jul 23 · DOI: 10.1016/j.appet.2026.108723
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100300
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1834580
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism · 2026 Jul · DOI: 10.1002/edm2.70291
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Jul 22 · DOI: 10.1111/obr.70198
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111322
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
Internal and emergency medicine · 2026 Jul 23 · DOI: 10.1007/s11739-026-04468-x
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
BMJ open · 2026 Jul 23 · DOI: 10.1136/bmjopen-2026-118191
Advances in proteomics research related to semaglutide: evidence from humans and animals.
Journal of endocrinological investigation · 2026 Jul 23 · DOI: 10.1007/s40618-026-02989-y
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit · 2026 Jun 28 · DOI: 10.26719/2026.32.6.394
AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
Nature communications · 2026 Jul 22 · DOI: 10.1038/s41467-026-73370-z
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Biological psychiatry · 2026 Jul 22 · DOI: 10.1016/j.biopsych.2026.07.010
When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.
Fundamental & clinical pharmacology · 2026 Jul · DOI: 10.1111/fcp.70109
Can semaglutide influence tumor biomarkers? Insight from a clinical case.
Journal of food and drug analysis · 2026 Jun 15 · DOI: 10.38212/2224-6614.3594
Hormonal Contraception and Initiation of Semaglutide Therapy.
JAMA network open · 2026 Jul 1 · DOI: 10.1001/jamanetworkopen.2026.24382
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Obesity surgery · 2026 Jul 22 · DOI: 10.1007/s11695-026-08854-4
Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes.
The Canadian journal of cardiology · 2026 Jul 22 · DOI: 10.1016/j.cjca.2026.05.013
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.
Nature communications · 2026 Jul 21 · DOI: 10.1038/s41467-026-75202-6
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
Translational research : the journal of laboratory and clinical medicine · 2026 Jul 21 · DOI: 10.1016/j.trsl.2026.07.008
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
The Journal of clinical endocrinology and metabolism · 2026 Jul 21 · DOI: 10.1210/clinem/dgag290
Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit.
Surgical endoscopy · 2026 Jul 20 · DOI: 10.1007/s00464-026-13149-x
Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations.
Indian pediatrics · 2026 Jul 20 · DOI: 10.1007/s13312-026-00408-2
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
The Journal of clinical psychiatry · 2026 Jul 15 · DOI: 10.4088/JCP.25m16212
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.
Diabetes, obesity & metabolism · 2026 Jul 19 · DOI: 10.1111/dom.71076
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.
Scientific reports · 2026 Jul 18 · DOI: 10.1038/s41598-026-62312-w
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 16 · DOI: 10.1016/j.numecd.2026.104872
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 7 · DOI: 10.1016/j.numecd.2026.104859
Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction.
Retina (Philadelphia, Pa.) · 2026 Aug 1 · DOI: 10.1097/IAE.0000000000004884
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.
Current opinion in HIV and AIDS · 2026 Jul 17 · DOI: 10.1097/COH.0000000000001059
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
Cell reports · 2026 Jul 17 · DOI: 10.1016/j.celrep.2026.117718
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
JAMA health forum · 2026 Jul 2 · DOI: 10.1001/jamahealthforum.2026.2207
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Surgical endoscopy · 2026 Jul 17 · DOI: 10.1007/s00464-026-13147-z
Peripheral artery disease: advances in medical therapy.
European heart journal · 2026 Jul 17 · DOI: 10.1093/eurheartj/ehag516
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 Jul 17 · DOI: 10.1111/jdv.70614
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1870649
Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.
European journal of case reports in internal medicine · 2026 · DOI: 10.12890/2026_006649
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Cureus · 2026 Jun · DOI: 10.7759/cureus.110952
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study.
Journal of the American Heart Association · 2026 Jul 17 · DOI: 10.1161/JAHA.125.046302
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
British journal of clinical pharmacology · 2026 Jul 16 · DOI: 10.1002/bcp.70711
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2026 Jul 16 · DOI: 10.1016/j.ejvs.2026.07.037